Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257
/PRNewswire/ -- Treadwell Therapeutics, a clinical stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced...
Mark Bray Spindle Assembly Checkpoint Drug Administration Investigational New Drug Treadwell Chief Scientific Officer Michael Tusche
Source: prnewswire.com